Artificial intelligence is becoming part of everyday clinical care. The rules governing it are struggling to keep up.
A new analysis from The Regulatory Review argues that hospitals are adopting AI-powered diagnostic and decision-support tools faster than they can develop the oversight needed to use them safely and consistently.
The challenge isn't that hospitals are behaving irresponsibly.
It's that regulatory frameworks designed for traditional medical devices weren't built for software capable of adapting, learning and changing after deployment.
Most clinical AI systems today are cleared through the FDA's existing medical device pathways, processes originally designed for static products such as imaging equipment or pacemakers.
AI doesn't behave like those products.
Why Static Rules Struggle With Adaptive Software
Machine learning models used for diagnostics, triage and treatment recommendations can change in performance as they encounter new patient populations and clinical environments.
A model that performs exceptionally well during clinical testing may behave differently once deployed across hospitals serving more diverse patients.
That's where regulators face a growing challenge.
The FDA has proposed frameworks for "predetermined change control plans," allowing developers to define how models may evolve after approval. Critics, however, argue those safeguards still fall short of detecting real-world model drift over time.
Hospitals face another obstacle.
Many lack the internal expertise to independently audit AI systems and instead rely heavily on performance data supplied by vendors themselves.
That creates an uncomfortable dynamic: the companies selling AI systems are often the primary source of evidence that those systems continue performing as intended.
"Clinical AI is advancing faster than the governance systems designed to oversee it."
Who's Accountable When Something Goes Wrong?
Liability becomes far less straightforward when AI contributes to a clinical decision.
If a patient is harmed following an AI-assisted diagnosis, responsibility could potentially fall on the physician, the hospital, the software developer, or some combination of all three.
Legal scholars cited in the analysis argue that existing malpractice and product liability laws were never designed for this kind of shared decision-making environment.
Meanwhile, adoption continues to accelerate.
Hospitals nationwide are integrating AI into radiology, pathology, sepsis prediction and administrative workflows, driven by staffing shortages, rising healthcare costs and pressure to improve efficiency.
That rapid deployment, combined with evolving regulation, is widening the governance gap.
A Familiar Pattern in Emerging Technology
Healthcare isn't the first industry where innovation has outpaced regulation.
Fintech, ride-sharing and social media all experienced similar periods where adoption moved faster than oversight.
Healthcare, however, carries far greater consequences.
Mistakes don't simply create financial losses. They can directly affect patient outcomes.
Rather than waiting for comprehensive federal legislation, The Regulatory Review suggests hospitals should strengthen governance internally by establishing dedicated AI oversight committees, conducting ongoing performance audits and creating clearer contractual responsibilities with technology vendors.
Some health systems have already begun implementing these measures.
There is still no widely accepted national standard for what responsible AI governance inside a hospital should look like.
What This Means for Miami
South Florida's hospital systems and health-tech startups are already part of this conversation.
Miami has become an increasingly important hub for digital health innovation, with several local healthcare providers exploring AI-powered diagnostic and administrative tools.
As expectations around AI governance continue to rise, hospitals across the region will likely face growing pressure to formalize oversight processes, not only to satisfy regulators but also to strengthen patient confidence.
For Miami's health-tech startups, the governance gap also represents an opportunity.
Companies developing AI auditing, compliance and monitoring platforms could find growing demand from healthcare providers seeking independent oversight as regulators, insurers and investors place greater scrutiny on how clinical AI systems are deployed and monitored.